Functional evaluation of genetic and environmental regulators of P450 mRNA levels

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Wang, Dazhi ^a,b   Jiang, Zhengwen ^b   Shen, Zhongyang ^c   Wang, Hui ^c   Wang, Beilan ^b   Shou, Weihua ^a,b   Zheng, Hong ^c   Chu, Xun ^a,b   Shi, Jinxiu ^b   Huang, Wei ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMIDE; AROMATIC HYDROCARBON; CIS ACTING ELEMENT; ENVIRONMENTAL CHEMICAL; HALOGENATED ARYL HYDROCARBON; HETEROCYCLIC AROMATIC AMINE AMIDE; MESSENGER RNA; POLYCYCLIC AROMATIC HYDROCARBON; TRANS ACTING FACTOR; UNCLASSIFIED DRUG; CYTOCHROME P450;

18SRRNA GENE; ACTB GENE; ADULT; AHR GENE; ARNT GENE; ARTICLE; CAR GENE; CHINESE; CONTROLLED STUDY; COPY NUMBER VARIATION; CYP1A1 GENE; CYP1A2 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; CYP3A5 GENE; GAPDH GENE; GENE; GENE INTERACTION; GENE REGULATORY NETWORK; GENETIC ANALYSIS; GENETIC VARIABILITY; HNF1A GENE; HNF4A GENE; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; P450 GENE; PXR GENE; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; USF1 GENE; ALLELE; ENVIRONMENT; ENZYMOLOGY; ESSENTIAL GENE; GENE EXPRESSION PROFILING; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; DNA COPY NUMBER VARIATIONS; ENVIRONMENT; GENE EXPRESSION PROFILING; GENE-ENVIRONMENT INTERACTION; GENES, ESSENTIAL; HUMANS; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 80053611043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024900     Document Type: Article

References (33)

1. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14: 1-18.
2. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30: 1108-1114.
3. Gonzalez FJ, Nebert DW, (1990) Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet 6: 182-186.
4. Martinez-Jimenez CP, Castell JV, Gomez-Lechon MJ, Jover R, (2006) Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1. Mol Pharmacol 70: 1681-1692.
5. Nebert DW, Vesell ES, (2004) Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 500: 267-280.
6. Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, Castell JV, (2001) Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393: 308-315.
7. Yang X, Zhang B, Molony C, Chudin E, Hao K, et al. (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20: 1020-1036.
8. Wortham M, Czerwinski M, He L, Parkinson A, Wan YJ, (2007) Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35: 1700-1710.
9. Li W, Harper PA, Tang BK, Okey AB, (1998) Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem Pharmacol 56: 599-612.
10. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ, (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279: 23847-23850.
11. Rebbeck TR, (2000) More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 92: 76.
12. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, et al. (2001) Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284: 455-460.
13. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391.
14. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW, (2002) Allelic variation in human gene expression. Science 297: 1143.
15. Martin J, Cleak J, Willis-Owen SA, Flint J, Shifman S, (2007) Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance. Mol Psychiatry 12: 421-422.
16. Cirulli ET, Goldstein DB, (2007) In vitro assays fail to predict in vivo effects of regulatory polymorphisms. Hum Mol Genet 16: 1931-1939.
17. Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, et al. (2008) Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 18: 781-791.
18. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, et al. (1989) Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 3: 1399-1408.
19. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
20. Jung D, Kullak-Ublick GA, (2003) Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37: 622-631.
21. Qadri I, Iwahashi M, Kullak-Ublick GA, Simon FR, (2006) Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression. Mol Pharmacol 70: 627-636.
22. Uno Y, Sakamoto Y, Yoshida K, Hasegawa T, Hasegawa Y, et al. (2003) Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J Hum Genet 48: 594-597.
23. Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, et al. (2004) Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 428: 493-521.
24. Ueda R, Iketaki H, Nagata K, Kimura S, Gonzalez FJ, et al. (2006) A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 69: 1924-1930.
25. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL, (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353: 16-28.
26. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, et al. (2003) Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43: 84-91.
27. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, et al. (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34: 1966-1975.
28. Chen Y, Kissling G, Negishi M, Goldstein JA, (2005) The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther 314: 1125-1133.
29. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM, (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199: 193-209.
30. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F, (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274: 516-520.
31. Sachse C, Brockmoller J, Bauer S, Roots I, (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295.
32. Gaedigk A, Bhathena A, Ndjountche L, Pearce RE, Abdel-Rahman SM, et al. (2005) Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 5: 173-182.
33. Jiang Z, Zhang X, Deka R, Jin L, (2005) Genome amplification of single sperm using multiple displacement amplification. Nucleic Acids Res 33: e91.